Assenagon Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Assenagon Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Hold	364,173	–	–	﹤0.01%	920
2026 Q1	$1.71M	Sell	364,173 -228,523	-39%	-$1.16M	﹤0.01%	800
2025 Q4	$2.52M	Sell	592,696 -137,271	-19%	-$521K	﹤0.01%	794
2025 Q3	$2.33M	Buy	729,967 +9,947	+1%	+$22.4K	﹤0.01%	797
2025 Q2	$1.63M	Buy	720,020 +8,566	+1%	+$13.8K	﹤0.01%	820
2025 Q1	$452K	Buy	711,454 +111,604	+19%	+$86.5K	﹤0.01%	1030
2024 Q4	$618K	Sell	599,850 -1,044,318	-64%	-$1.12M	﹤0.01%	1171
2024 Q3	$1.94M	Buy	1,644,168 +405,669	+33%	+$515K	﹤0.01%	977
2024 Q2	$1.51M	Buy	1,238,499 +833,825	+206%	+$1.66M	﹤0.01%	989
2024 Q1	$882K	Hold	404,674	–	–	﹤0.01%	1082
2023 Q4	$627K	Sell	404,674 -21,247	-5%	-$27.9K	﹤0.01%	1211
2023 Q3	$549K	Sell	425,921 -242,111	-36%	-$381K	﹤0.01%	1181
2023 Q2	$1.15M	Hold	668,032	–	–	﹤0.01%	937
2023 Q1	$1.01M	Sell	668,032 -246,868	-27%	-$558K	﹤0.01%	1045
2022 Q4	$1.46M	Sell	914,900 -150,492	-14%	-$223K	0.01%	936
2022 Q3	$1.54M	Buy	+1,065,392	New	+$1.64M	0.01%	787
2021 Q4	–	Sell	-27,774	Closed	-$141K	–	1452
2021 Q3	$141K	Sell	27,774 -465,239	-94%	-$2.49M	﹤0.01%	1250
2021 Q2	$3.12M	Buy	493,013 +288,872	+142%	+$2.25M	0.01%	587
2021 Q1	$1.58M	Sell	204,141 -14,622	-7%	-$116K	0.01%	771
2020 Q4	$1.43M	Buy	218,763 +45,887	+27%	+$328K	0.01%	618
2020 Q3	$1.15M	Sell	172,876 -80,824	-32%	-$599K	0.01%	756
2020 Q2	$2.11M	Buy	+253,700	New	+$2.36M	0.01%	578
2020 Q1	–	Sell	-224,640	Closed	-$1.87M	–	830
2019 Q4	$1.87M	Buy	224,640 +148,740	+196%	+$1M	0.01%	457
2019 Q3	$560K	Sell	75,900 -48,500	-39%	-$478K	﹤0.01%	679
2019 Q2	$1.4M	Buy	+124,400	New	+$1.3M	0.01%	632
2018 Q4	–	Sell	-19,638	Closed	-$363K	–	1026
2018 Q3	$363K	Buy	+19,638	New	+$447K	﹤0.01%	734

Other funds holding CTMX

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

CPC

Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Assenagon Asset Management's CTMX Position: Q2 2026 in Review

Assenagon Asset Management held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 364,173 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #920.

Assenagon Asset Management first reported a position in CTMX in Q3 2018 and has held it in 26 quarters since. The position peaked at $3.12M in Q2 2021. 7 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Assenagon Asset Management held 364,173 shares of CytomX Therapeutics worth $1.37M as of Q2 2026.
Assenagon Asset Management left its CytomX Therapeutics share count unchanged in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #920 holding.
Assenagon Asset Management first reported a position in CytomX Therapeutics in Q3 2018 and has held it in 26 quarters since.
Assenagon Asset Management's CytomX Therapeutics position peaked at $3.12M in Q2 2021.
7 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.